By Lina carolina 
The intricate dance between a developing tumor and the body’s defenses has long been a focus of oncological research. A crucial element in this battleground is the tumor stroma, a complex microenvironment that supports tumor growth and progression. Within this stroma, blood and lymphatic vessels play vital roles in nutrient supply and waste removal. Traditionally, the development of new lymphatic vessels, a process known as lymphangiogenesis, has been viewed as a harbinger of poor prognosis, largely due to its association with the spread of cancerous cells to distant organs, a process termed metastasis. However, groundbreaking research from the University of Geneva (UNIGE) has unveiled a surprising and potentially revolutionary role for these lymphatic vessels and the cells that constitute their walls. A team of scientists at UNIGE has discovered that an enzyme expressed by these lymphatic endothelial cells appears to be a key player in supporting the immune system, particularly when it’s activated by anti-cancer treatments. This discovery, published in the prestigious journal Nature Communications, offers a novel avenue for improving the efficacy of immunotherapies, a class of cancer treatments that harness the body’s own immune system to fight disease.
Challenging Conventional Wisdom: The Complex Role of Lymphatic Vessels
For decades, the primary concern regarding lymphangiogenesis in cancer has been its direct link to metastasis. The proliferation of lymphatic vessels provides ready pathways for tumor cells to enter the circulatory system and travel to lymph nodes and other organs, establishing secondary tumors. This understanding led to considerable research efforts aimed at blocking or inhibiting lymphangiogenesis, with the hope of curtailing metastatic spread. However, these therapeutic strategies have met with limited success, prompting researchers to re-examine the multifaceted role of lymphatic vessels within the tumor microenvironment.
"While it is true that lymphatic vessels promote metastasis, they are also essential for transporting immune cells and activating the anti-tumour immune response," explains Stéphanie Hugues, a full professor in the Department of Pathology and Immunology and at the Geneva Centre for Inflammation Research in UNIGE’s Faculty of Medicine, who spearheaded this research. "Their role is therefore more complex than we imagined, which is why we wanted to understand how the cells that make them up respond to the tumour microenvironment in order to influence the immune response." This shift in perspective, moving beyond a singular focus on metastasis to a more nuanced understanding of immune cell trafficking and regulation, was the catalyst for the UNIGE team’s investigation.
The research team’s initial hypothesis was that by understanding the molecular dialogue between tumor cells, stromal components, and lymphatic endothelial cells, they could identify targets to either inhibit detrimental functions or enhance beneficial ones. Their meticulous examination of gene expression patterns in lymphatic endothelial cells from both melanoma tumors and healthy mouse skin laid the foundation for their pivotal discovery.
A Surprising Ally: The CH25H Enzyme and its Immunomodulatory Function
The UNIGE researchers meticulously analyzed the gene expression profiles of lymphatic endothelial cells (LECs) lining the vessels within tumors. They observed a significant upregulation of an enzyme, identified as CH25H, in the LECs associated with melanomas compared to those in healthy tissue. This finding was not confined to preclinical models; the team confirmed its presence in human melanoma samples. Crucially, they found a strong correlation: the greater the density of lymphatic vessels within a melanoma, the higher the expression of the CH25H enzyme.
Further analysis revealed a remarkable clinical implication. Patients exhibiting higher levels of CH25H expression in their melanomas generally exhibited a better prognosis. This positive association was even more pronounced in patients who had received a specific type of immunotherapy known as immune checkpoint inhibitors. These drugs work by releasing the brakes on the immune system, allowing T cells to recognize and attack cancer cells more effectively.
The function of the CH25H enzyme is to catalyze the conversion of cholesterol into 25-hydroxycholesterol (25-OHC), a cholesterol metabolite that plays a recognized role in antiviral immunity. However, the UNIGE study elucidated its previously unrecognized impact on the anti-tumor immune response. The tumor microenvironment is notoriously immunosuppressive, actively producing factors that dampen the activity of immune cells, thus allowing the tumor to evade destruction. The research suggests that 25-OHC, produced by CH25H in LECs, acts as a counteracting force, preventing these immunosuppressive factors from inhibiting immune cell activation. In essence, the enzyme appears to be a crucial component in disarming the tumor’s defenses by fostering a more permissive environment for anti-tumor immunity.
"This enzyme’s function is to convert cholesterol into 25-hydroxycholesterol, a cholesterol metabolite important in antiviral immunity," the study abstract notes. "In melanoma, this enzyme seems to also have an impact on the immune system, probably by undermining the tumour’s defence mechanisms. Indeed, the tumour microenvironment naturally produces factors that inhibit the activation of immune cells. However, 25-hydroxycholesterol prevents this inhibition, and therefore enables better activation of anti-tumour immunity." This mechanism represents a significant departure from the prevailing view of lymphatic vessels solely as conduits for tumor spread.
Experimental Validation: Unraveling the Enzyme’s Impact
To definitively establish the role of CH25H and 25-OHC in anti-tumor immunity, the UNIGE team conducted targeted experiments in mouse models. They genetically engineered mice to lack the CH25H enzyme in their lymphatic endothelial cells. The results were striking. The absence of CH25H led to a dramatic reduction in 25-OHC levels within melanoma tumors. This biochemical change was accompanied by a significant suppression of immune activity within the tumor microenvironment. Consequently, the mice with compromised CH25H function exhibited a markedly less effective immune response against the melanoma, with tumors progressing more aggressively.
Conversely, when mice were vaccinated with tumor antigens, a strategy designed to prime their immune systems against the cancer, the researchers observed a clear increase in CH25H enzyme expression and a corresponding surge in 25-OHC production. This enhanced production of 25-OHC correlated directly with improved activation of anti-tumor immune cells. This experimental data powerfully reinforces the clinical observations, demonstrating a direct link between CH25H activity, 25-OHC levels, and the efficacy of the immune response against cancer.
This correlation between CH25H expression and treatment response is particularly significant for the future of cancer therapy. "Our discovery could therefore provide a biomarker for predicting the success of immunotherapy, enabling treatments to be adjusted according to the specific characteristics of each patient," Professor Hugues emphasized. The ability to predict which patients are most likely to benefit from specific immunotherapies could lead to more personalized and effective treatment regimens, avoiding unnecessary side effects and optimizing resource allocation.
Implications for Future Cancer Therapies: Beyond Blocking Metastasis
The findings of the UNIGE study have profound implications for how we approach cancer treatment, particularly in the realm of immunotherapies. The long-held belief that all aspects of lymphangiogenesis are detrimental to cancer patients is being challenged by this research. Instead, the study highlights the nuanced and potentially beneficial roles that lymphatic endothelial cells and their products can play.
"Lymphatic vessels have long been regarded as simple transport routes," the authors conclude. "Our work clearly shows the much more complex role of the cells that make them up. Highly malleable, they respond to the tumour microenvironment and to modulations by the immune system. The stroma is therefore not just a scaffold for the tumour but constitutes a highly complex microworld with both beneficial and pathological roles. We therefore recommend not targeting lymphangiogenesis as a whole but modulating specific functions to fight the disease more effectively."
This suggests a paradigm shift in therapeutic strategies. Instead of broadly inhibiting lymphangiogenesis, future interventions might focus on selectively enhancing the beneficial functions of LECs, such as promoting the production of 25-OHC, or modulating their interaction with immune cells. This targeted approach could potentially boost the effectiveness of existing immunotherapies and open doors to entirely new therapeutic modalities.
The research team’s work, initiated approximately four years ago with the initial hypothesis that lymphatic vessels’ role was more complex than understood, represents a significant leap forward in our understanding of the tumor microenvironment and its influence on immune responses. The progression from initial gene expression analysis to experimental validation and clinical correlation demonstrates a robust scientific inquiry. While further research is undoubtedly needed to fully translate these findings into clinical practice, the discovery of CH25H’s immunomodulatory role offers a beacon of hope for improving the lives of cancer patients. The potential for developing novel diagnostic biomarkers and therapeutic agents based on this discovery underscores the vital importance of continued investment in fundamental cancer research. The complex interplay within the tumor stroma, once viewed with suspicion, is now revealing hidden allies in the fight against cancer.
